CymaBay rises on expansion of FDA tag for liver disease drug

CymaBay Therapeutics

23/10/2023 16:57

** Shares of therapy developer CymaBay Therapeutics  CBAY.O 
rise ~6.5% to $14.50
    ** Co says the U.S. FDA has expanded the "breakthrough
therapy" designation for its drug seladelpar, intended against
primary biliary cholangitis (PBC), to include treatment for
itching in adults without scarring of the liver or with
asymptomatic liver scarring
    ** PBC is a chronic disease in which the small bile ducts in
the liver become injured and inflamed and are eventually
destroyed
    ** "Breakthrough therapy" tag is meant to speed up the
development and review of drugs to treat a serious condition or
unmet medical need    
    ** Including session's move, shares have more than doubled
YTD

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))